Efficacy and safety evaluation of pregabalin treatment over 52weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial

Journal of Diabetes Investigation

Volumn 2, Issue 6, 2011, Pages 457-463

  Satoh, Jo ^a   Yagihashi, Soroku ^b   Baba, Masayuki ^c   Suzuki, Makoto ^d   Arakawa, Akio ^d   Yoshiyama, Tamotsu ^d  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d PFIZER INC   (United States)

Author keywords

Diabetic peripheral neuropathy; Neuropathic pain; Pregabalin

Indexed keywords

PLACEBO; PREGABALIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIC ACTIVITY; ANGINA PECTORIS; ARTICLE; BONE NECROSIS; BRAIN INFARCTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETIC NEUROPATHY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FACE EDEMA; FEMALE; FEMUR HEAD NECROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPERURICEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; NEUROPATHIC PAIN; NEUTROPHIL COUNT; OCCULT BLOOD; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PULSE RATE; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; VISUAL ANALOG SCALE; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84859868230     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00122.x     Document Type: Article

References (22)

1. Boulton AJ, Vinik AI, Arezzo JC, et al. ; American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
2. Chan AW, MacFarlane IA, Bowsher DR, et al. Chronic pain in patients with diabetes mellitus: comparison with a non-diabetic population. Pain Clin 1990; 3: 147-159.
3. Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy: correlation with clinical signs and symptoms. Diabetes Res Clin Pract 2007; 77(Suppl. 1): S184-S189.
4. Hanaoka K, Ogawa S, Hotta T, et al. Present state and future prospects of treatment of neuropathic pain in Japan: recommendations by the consensus conference between experts. Pain Clin 2009; 30: 1395-1408 (Japanese).
5. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-1635.
6. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006; 16: S128-S133.
7. Dooley DJ, Donovan CM, Meder WP, et al. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002; 45: 171-190.
8. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-251.
9. Attal N, Cruccu G, Haanpää M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2006; 17: 1113-1123.
10. Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14-week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011; 28: 109-116.
11. Diabetic Neuropathy Study Group. Simplified diagnostic criteria for distal symmetric polyneuropathy. Peripher Nerve 2003; 14: 225 (Japanese).
12. Yamaguchi M, Kumano H, Yamauchi Y, et al. The development of a Japanese version of the short-form McGill pain questionnaire. J Jpn Soc Pain Clin 2007; 14: 9-14.
13. Seino Y, Tajima N, Kadowaki T, et al. The Research and Examination Committee on Diabetic Diagnosis Criteria. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Jpn Diabetes Soc 2010; 53: 450-467 (Japanese).
14. Japan Diabetes Society. Diabetic foot. In: Japan Diabetes Society. (ed). Evidence-based Guidelines on Clinical Practice for Diabetes, 2nd edn. Nankodo, Tokyo, 2007; 93-104 (Japanese).
15. Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008; 8: 33-45.
16. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-638.
17. Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008; 12: 203-213.
18. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6: 253-260.
19. Lesser H, Sharma U, Lamoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-2110.
20. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115: 254-263.
21. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105-121.
22. Haslam C, Nurmikko T. Pharmacological treatment of neuropathic pain in older persons. Clin Interv Aging 2008; 3: 111-120.